Intradigm Corporation

Healthcare Biotechnology

Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The companyâ€™s expertise in drug development and delivery serves as the foundation...

Founded in 2000
Homepage: http://www.intradigm.com/
Total money raised: $37.4M

Headquarters

94303 3350 W Bayshore Rd, Suite 100

Palo Alto
USA CA

Phone: (650) 855 9696

Updated on Apr 22, 2010
Intradigm Corporation at CrunchBase

Tags: drug oncology therapeutics treatment

December, 2009

Intradigm Corporation was acquired by Silence Therapeutics

Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company

silence-therapeutics.com

January, 2009

Intradigm Corporation raised $21.4M in a Series B round from MP Healthcare Venture Management, Frazier Healthcare Ventures, Astellas Venture Management, MediBic Alliance, Alta Partners, Lilly Ventures, Novartis Venture Fund, and Roche Venture Fund

Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive

fiercebiotech.com

November, 2006

Intradigm Corporation raised $16M in a Series A round from Alta Partners, Frazier Healthcare Ventures, Emerging Technology Partners, Novartis Venture Funds, and MediBic Alliance

INTRADIGM ANNOUNCES SIGNIFICANT ENHANCEMENTS OF THE COMPANY CAPABILITIES, A NEW SERIES A FINANCING AND IMPORTANT ADDITION TO SENIOR MANAGEMENT TEAM

2000

Intradigm Corporation was founded in 2000